Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Avacta Group plc ( (GB:AVCT) ) has provided an announcement.
Avacta Therapeutics, the clinical-stage biopharmaceutical arm of Avacta Group plc, specializes in oncology-focused life sciences and is developing its proprietary pre|CISION tumor-activated delivery platform for peptide drug conjugates that target fibroblast activation protein in cancer tissue. Its lead program, faridoxorubicin AVA6000, and second candidate, FAP-Exd AVA6103, aim to improve the safety and efficacy profile of highly potent chemotherapies by localizing drug release within tumors.
The company has announced a 2026 Science Day for investors, titled “The Next Chapter of pre|CISION,” to be held at the Royal Society of Chemistry in London on May 6, 2026, where management will present recent scientific progress and future aspirations for the platform. The event, which has limited in-person capacity and will also be recorded for later online access, underscores Avacta’s efforts to engage the investment community and highlight the strategic potential of its evolving pre|CISION pipeline in the competitive oncology therapeutics market.
The most recent analyst rating on (GB:AVCT) stock is a Hold with a £48.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.
Spark’s Take on AVCT Stock
According to Spark, TipRanks’ AI Analyst, AVCT is a Neutral.
Avacta Group plc’s overall stock score is primarily impacted by its weak financial performance and bearish technical indicators. While there is some progress in clinical programs, financial constraints and lack of partnerships remain significant risks. The stock’s valuation is unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on AVCT stock, click here.
More about Avacta Group plc
Avacta Therapeutics, a unit of Avacta Group plc, is a clinical-stage biopharmaceutical company focused on expanding access to highly potent cancer therapies through its proprietary pre|CISION tumor-activated drug delivery platform. The company develops peptide drug conjugates that use a fibroblast activation protein trigger to concentrate cytotoxic payloads in the tumor microenvironment while limiting systemic exposure, with lead candidates including faridoxorubicin AVA6000 and FAP-Exd AVA6103 in oncology indications with significant unmet need.
Average Trading Volume: 1,782,452
Technical Sentiment Signal: Hold
Current Market Cap: £277.8M
For a thorough assessment of AVCT stock, go to TipRanks’ Stock Analysis page.